High Numbers Reported for Russian Vaccine

Nov 25, 2020

Russia has announced that its candidate vaccine against SARS-CoV-2 has exhibited an efficacy rate exceeding 95 percent in an initial analysis of its clinical trial data, the Financial Times reports.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Should Also Work

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

Worries About Increased Deadliness

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

Merck Stops SARS-CoV-2 Vaccine Development

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

PLOS Papers on Rare Venous Thromboembolism Variant, Vector Mosquito LncRNAs, More

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.

Featured White Papers

Use of the LumiraDx SARS-CoV-2 Antigen Test in pediatric practice

Performance evaluation of the LumiraDx SARS-CoV-2 Antigen Test to aid diagnosis of acute COVID-19 at the point of care

An evaluation of the detection of SARS-CoV-2 antigen in a cohort of symptomatic and asymptomatic patients: Report from the evaluation of SKUP

Agena Bioscience’s SARS-CoV-2 Tests: Providing Resilience Against the Emergence of New Variants

Feb

11

Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb

17

Featured Webinar

Single-Cell Multiomics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19

Host immune responses play a central role in controlling SARS-CoV-2 infection, but they remain incompletely characterized and understood.

Feb

18

Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression.

Feb

23

Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before.

Menu